Open Access Open Access  Restricted Access Subscription or Fee Access

Extrapolations of Periwinkle Secondary Metabolites as Multitarget Inhibitor of Breast Cancer Proteins

Aparna Prasad


Objective: Breast cancer is considered as one of the most common and dangerous forms of cancer. It is a significant public health issue on a global scale. The study estimates that 10.0 million people will die from cancer this year, and 19.3 million people will develop the disease overall (BC). In this computation approach nowadays emphasises for new drug discovery, the target protein EGFR (5UGB), ER (2QGT), and PI3KA (4OYS) were chosen to perform molecular docking against the derivatives of periwinkle Catharanthus phytochemical and FDA approved drugs. Its pharmacological characteristics and its therapeutic analysis were investigated. Methods: The study was based on a computational approach using different phytocompounds for evaluation of their inhibitory potential against the target proteins EGFR, ER, and PI3KA. The protein molecular docking was conducted systematically using IMPAAT, PubChem, PDB, Open Bable, BIOVIA Discovery Studio Visualizer, PDB sum generate, PyRx and ADMETlab 2.0. Result: The docking result revealed that the ligands selected have the best binding affinity with all the three target proteins. Conclusion: The ligands could potentially be used to treat breast cancer in the future approaches for studying the urge ligands in vitro and in vivo analysis in order to create novel breast cancer inhibitors.

Full Text:



Sharma GN, Dave R, Sanadya J, Sharma P, Sharma K. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res. 2010; 1(2): 109–126.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021; 71(3): 209–249.

Kabel AM, Baali FH. Breast cancer: insights into risk factors, pathogenesis, diagnosis and management. Journal of Cancer Research and Treatment. 2015 Sep 15; 3(2): 28–33.

Singletary SE. Rating the risk factors for breast cancer. Ann Surg. 2003; 237(4): 474.

Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer: Targets and Therapy. 2019; 11: 151–164.

Nakai K, Hung MC, Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016; 6(8): 1609–1623.

Foley J, Nickerson NK, Nam S, Allen KT, Gilmore JL, Nephew KP, Riese II, DJ. EGFR signaling in breast cancer: bad to the bone. In Seminars in cell & developmental biology. 2010 Dec; 21(9): 951–960. Academic Press.

McGovern SL, Qi Y, Pusztai L, Symmans WF, Buchholz TA. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Res. 2012; 14(3): 1–11.

Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Symmans WF, et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen- positive tumors. Clin Cancer Res. 2003; 9(7): 2406–2415.

Hilton J, Weberpals J, Lorimer I, Amin S, Islam S, Daneshmand M, Verma S, et al. Abstract C1: BRCA1 protein levels and PI3KA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis. Mol Cancer Ther. 2011; 10(11_Suppl): C1.

Sathiya S, Karthikeyan B, Jaleel CA, Azooz MM, Iqbal M. Antibiogram of Catharanthus roseus extracts. Global J Mol Sci. 2008; 3(1): 01–07.

Gawade M, Zaware M, Gaikwad C, Kumbhar R, Chavan T. Catharanthus roseus L.(Periwinkle): An herb with impressive health benefits & pharmacological therapeutic effects. International Journal of Agriculture and Nutrition. 2021; 4(2): 52–57.

Das S, Sharangi AB. Madagascar periwinkle (Catharanthus roseus L.): Diverse medicinal and therapeutic benefits to humankind. J Pharmacogn Phytochem. 2017; 6(5): 1695–1701.

Dada WP, Nilima W. Vinca Rosea: As a Potent Anti-Cancer Agent. World J Pharm Res. 2022; 11(1): 781–794.

Ahmed B, Ashfaq UA, ul Qamar MT, Ahmad M. Anti-cancer potential of phytochemicals against breast cancer: Molecular docking and simulation approach. Bangladesh J Pharmacol. 2014; 9(4): 545–50.

Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Siegel RL, et al. Breast cancer statistics, 2022. CA: Cancer J Clin. 2022; 72(6): 524–541.

Acharya R, Chacko S, Bose P, Lapenna A, Pattanayak SP. Structure based multitargeted molecular docking analysis of selected furanocoumarins against breast cancer. Sci Rep. 2019; 9(1): 1–13.

Yang Y, Tao R, Shu X, Cai Q, Wen W, Gu K, Zheng W, et al. Incorporating polygenic risk scores and nongenetic risk factors for breast cancer risk prediction among Asian women. JAMA Netw Open. 2022; 5(3): e2149030.

Hossein-Nejad-Ariani H, Althagafi E, Kaur K. Small peptide ligands for targeting EGFR in triple negative breast cancer cells. Sci Rep. 2019; 9(1): 1–10.

Williams SD, Smith TM, Stewart LV, Sakwe AM. Hypoxia-Inducible Expression of Annexin A6 Enhances the Resistance of Triple-Negative Breast Cancer Cells to EGFR and AR Antagonists. Cells. 2022; 11(19): 3007.

Ma S, Tang T, Probst G, Konradi A, Jin C, Li F, Guan KL, et al. Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER+ breast cancer. Nat Commun. 2022; 13(1): 1–17.

Akinnusi PA, Olubode SO, Adebesin AO, Nana TA, Shodehinde SA. Discovery of Promising Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), Estrogen Receptor (ER), and Phosphatidylinositol-3-kinase a (PI3Ka) for Personalized Breast Cancer Treatment. Cancer Inform. 2022; 21: 11769351221127862.

Araki K, Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 2018; 25(4): 392–401.

Vernieri C, Corti F, Nichetti F, Ligorio F, Manglaviti S, Zattarin E, de Braud F, et al. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. Breast Cancer Res. 2020; 22(1): 1–13.

Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Aapro M, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol. 1999; 17(5): 1413–1424.

Fraschini G, Yap HY, Hortobagyi GN, Buzdar A, Blumenschein G. Five‐day continuous‐infusion vinblastine in the treatment of breast cancer. Cancer. 1985; 56(2): 225–229.

Shah A, Bloomquist E, Tang S, Fu W, Bi Y, Liu Q, Pazdur R, et al. FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast CancerRibociclib for HR+ HER2− Metastatic Breast Cancer. Clin Cancer Res. 2018; 24(13): 2999–3004.



  • There are currently no refbacks.

Copyright (c) 2023 Research & Reviews: Journal of Oncology and Hematology